Compare Crispr Therapeutics AG (CRSP) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs VanEck Gold Miners ETF — how do they compare? Crispr Therapeutics AG trades at $53.78 (market cap $4.88B), while VanEck Gold Miners ETF trades at $89.14 (market cap $25.65B). The key difference: VanEck Gold Miners ETF is far larger — about 5.3× Crispr Therapeutics AG's market cap, and VanEck Gold Miners ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and VanEck Gold Miners ETF for 76 Days on average.
| CRSP | GDX | |
|---|---|---|
Market Cap | $4.88B | $25.65B |
Volume | 2,861,747 | 16,534,046 |
Sector | Health | — |
52-Week High | $74.92 | $115.84 |
52-Week Low | $44.34 | $68.28 |
Typical Hold Time | 77 Days | 76 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
GDX trades at $89.31, up 4.51% over the past 24 hours, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF faces headwinds from rising interest rates pressuring dividend stocks and a recent sell-off in metals. Support levels are clustered between $84 and $86, while resistance sits near $87 to $89. Recent news highlights institutional selling by firms like Allworth Financial and HB Wealth Management, though Ameritas Advisory Services increased its stake.
The outlook for GDX is cautious due to bearish technicals and macroeconomic pressures on gold miners. Opportunities exist if gold prices rebound, but risks include persistent rate hikes and volatility in commodity markets. Investors should weigh the ETF's leverage to gold against operational risks in the mining sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
